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We demonstrate here that immunizing na¨ ıve mice with low numbers of recombinant Bacille Calmette-Gu´ erin (rBCG) expressing
β-galactosidase (β-gal) generates predominant Th1 responses to both BCG and β-gal whereas infection with high numbers
generates a mixed Th1/Th2 response to both BCG and β-gal. Furthermore, the Th1 response to both BCG and β-gal is stable
when mice, pre-exposed to low numbers of rBCG, are challenged four months later with high numbers of rBCG. Thus the
Th1/Th2 phenotypes of the immune responses to β-gal and to BCG are “coherently” regulated. Such rBCG vectors, encoding
antigens of pathogens preferentially susceptible to cell-mediated attack, may be useful in vaccinating against such pathogens. We
discuss vaccination strategies employing rBCG vectors that are designed to provide protection against diverse inﬂuenza strains
or numerous variants of HIV-1 and consider what further experiments are essential to explore the possibility of realizing such
strategies.
1.Introduction
A rational approach to vaccination against a pathogen is
contingent upon a knowledge of the immunological corre-
lates that discriminate between immunity able to contain
the pathogen and immunity that fails to do so. Eﬀective
vaccination must guarantee the former type of immunity
undercircumstancewherethelattertypeofimmunity would
be generated upon natural infection of the na¨ ıve individual
[1]. Eﬀective vaccination of people, against a diversity of
pathogens, is achieved through guaranteeing a rapid and
large antibody, Th2 response upon natural infection by the
pathogen. Such vaccination is eﬀective only when antibody
is able to contain the pathogen and/or neutralize the toxins
the pathogen produces. However, there are other situations,
following infection by some intracellular pathogens or the
development of cancer, where the correlates of protection are
a predominant cell-mediated, CTL, Th1 response and where
responses with a substantial Th2, antibody component,
are associated with chronic or progressive disease [2]. In
these cases, it would appear that eﬀective vaccination must
generate a Th1 imprint upon the immune system that is
stable upon natural infection by the pathogen [3].
Mycobacterium bovis is responsible for tuberculosis of
cattle. An attenuated form of M. bovis, named BCG, is
currently the only available vaccine against Mycobacterium
tuberculosis, the pathogen primarily responsible for human
tuberculosis. Billions of individuals worldwide have been
inoculated with BCG in attempts to provide protection
against tuberculosis and leprosy. Moreover, these bacteria
can be used as vectors that express antigens of diverse
pathogens to raise immunity against these antigens. Several
recombinantBCGvectorshavebeenconstructedforvaccina-
tionagainstavarietyofbacterial,viral,orparasiticpathogens
[4].
There are several advantages in using rBCG vectors. Not
only does BCG act as an adjuvant, but its slow replication
allows for persistent, low level delivery of antigen to the2 Journal of Biomedicine and Biotechnology
host over a considerable time. Many observations show, in
diverse systems, that chronic stimulation with low amounts
of antigen can lead to the establishment of Th1 imprints
[2, 3, 5–7]. Additionally, advances in expression and delivery
of antigen by rBCG, hence increasing the availability of the
encoded antigens to the host immune system, have allowed
the development of vaccine vectors superior to those of
the past [4]. We are also encouraged to explore the use of
rBCG vectors in developing strategies of vaccination by the
remarkable safety record of BCG as a vaccination agent [8].
A critical question, when considering the use of rBCG
vectors to immunize against the encoded protein, is the
relationship between the nature of the immune response to
BCG and the nature of the response to the encoded protein.
This is particularly critical in those cases where there are
grounds for believing that the Th1/Th2 phenotype of the
response to the encoded antigen is likely critical to the degree
of protection provided by vaccination. It has been proposed
that the Th1/Th2 phenotype of the responses to BCG and
the encoded protein may be coordinately determined [1], a
phenomenon referred to as coherence. We set out to explore
whether, employing rBCG encoding β-galactosidase as a
model rBCG vector, the Th1/Th2 phenotypes of the immune
responses to BCG and to β-galactosidase are coherently
regulated.Shouldthisbethecase,itwouldlaythefoundation
forfurtherstudiesaimedatexaminingwhetherrBCGvectors
could be employed to establish Th1 imprints against those
pathogens preferentially susceptible to predominant cell-
mediated, Th1 responses.
2.MaterialsandMethods
2.1. Mice. Female mice were used in all experiments.
BALB/cJ mice were obtained from the animal colony at the
Department of Microbiology and Immunology, University
of Saskatchewan. All mice were housed at the animal care
facility within the Department and were at least 6 weeks
old at the time of immunization. Animal care and treatment
wereinaccordancewithstandardsapprovedbytheCanadian
Council on Animal Care.
2.2. Growth and Enumeration of rBCG. Dr. Emil Skamene
of McGill University provided M. bovis strain BCG Mon-
treal. The mycobacteria were propagated in Dubos medium
containing 0.5% bovine serum albumin and 0.05% Tween
80. Bacteria were enumerated by plating various dilutions
on Dubos agar plates after sonication for ﬁve seconds at a
p o w e ro u t p u to f5a n d5 0 %d u t yc y c l et ob r e a ku pc l u s t e r so f
bacteria. Colonies were counted fourteen days after plating,
and consequently numbers of bacteria are expressed as cfu.
2.3. Immunizations. Fourteen-day cultures of BCG or rBCG
were used for injections. The cells were pelleted by centrifu-
gation at 8000g for 30 minutes and washed three times by
repeated resuspension in saline containing 0.05% Tween 80
followed by centrifugation at 8000g for 20 minutes. After
the ﬁnal wash, the mycobacteria were resuspended in 1/100
of the original volume of culture, and serial dilutions were
performed from this stock as needed. BCG immunizations
were performed by either intradermal (i.d.) or intravenous
(i.v.) route. For i.d. injection, hair was removed from the
abdomen using a commercial depilatory two days prior to
injection. Injections were done using a 1cc syringe with
a 30-gauge needle attached. Mice were anesthetized, and
the skin of the abdomen was gently stretched to prevent it
from bunching up in front of the needle. With the bevel of
the needle facing upward, the needle was inserted several
millimeters horizontally into the skin and 25–50μl of the
BCG suspension containing the appropriate number of cfu
was injected. For i.v. injection, the desired number of BCG
cfu were injected in a 50μl volume into the lateral tail vein
using a 28-gauge needle.
Mice were immunized by the i.p. route with recombinant
β-gal (Sigma Chemicals, St. Louis, MO), either as a soluble
protein in phosphate-buﬀered saline (PBS) or adsorbed to
the aluminum hydroxide gel adjuvant, Alhydrogel (Superfos
Biosector, Vedbaek, Denmark) as indicated in the legend to
Figure 6.
2.4. ELISPOT Assay for Detection and Enumeration of
Antigen-Dependent IFNγ- and IL-4-Secreting Cells. The
ELISPOT assay for enumeration of BCG-speciﬁc cytokine
producing lymphocytes was performed on spleen cells as
previously described in detail [9]. For detection of β-gal-
speciﬁccytokine-producingcells,theprocedurewasidentical
except that puriﬁed soluble β-gal (Sigma Chemicals) was
used at 1μg/well for stimulation of lymphocytes.
2.5. Analysis of Antimycobacterial or Anti-β-gal Antibodies
by Enzyme Immunoassay. Blood from normal or infected
mice was collected by tail bleeding into serum separator
tubes(BectonDickinson,Rutherford,NJ).Afterallowingthe
samples to clot for at least several hours, individual serum
samples were harvested by centrifugation at approximately
5000g for 60 seconds. Sera were stored at −70
◦C until use.
The IgG1 and IgG2a serum antibody titers were determined
using an ELISA. Immulon-4 96-well polystyrene plates
(Dynatech Laboratories, Chantilly, VA) were coated with
either BCG antigen or with soluble β-gal antigen at a
concentrationof1μg/wellin100μlofPBSandtheprocedure
wasperformedasdescribedin[10].Thetiterwasdetermined
by plotting optical density against the log of the dilution
factorforeachsample.Theendpointtiterwasassignedasthe
point on the line at which the optical density was 0.5 above
the value for wells to which no serum was added.
2.6. Mycobacterial Expression Vectors. Dr. Mark Hanson
of MedImmune, Gaithersberg, MA, kindly provided the
mycobacterial expression vector pMV361::LacZ [11]. Vector
pMV361 is a chromosomal integrating vector in which
inserted genes are expressed as a fusion protein with the ﬁrst
six amino acids of the mycobacterial heat shock protein 60
(Hsp60).
2.7. Transformation of Competent M. bovis BCG. The
method of Parish and Stoker [12] was used to prepareJournal of Biomedicine and Biotechnology 3
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Figure 1: Immune response of four individual mice per group after i.v. immunization with diﬀerent doses of recombinant BCG (rBCGβgal)
or control rBCG expressing HIV gag protein (rBCGHgag). Immunization dose is indicated below each graph. Mice were immunized as
indicated under each graph. After 9 weeks, the mice were killed and the number of β-gal- and BCG-speciﬁc IFNγ- and IL-4-producing
cells in their spleens was determined by ELISPOT assay. The response in mice given a high dose of BCG transformed with a control vector
containing the HIV gag sequence is also shown. Open bars—IFNγ response to BCG; Black bars—IFNγ response to β-gal; Dark gray bars—
IL-4 response to BCG; Light gray bars—IL-4 response to β-gal. All values were corrected for background by subtracting the number of spots
observed in wells without antigen. Results are representative of two independent experiments.
electroporation-competent BCG. Transformation of com-
petent BCG was performed by electroporation using the
Gene Pulser II (BioRad). Electroporation-competent BCG
was removed from the freezer and immediately placed on ice
forseveralminutestoallowsamplestothaw.Onemicrogram
ofplasmidDNAwasaddedtothetube,andthecontentswere
mixed and placed on ice for ten minutes. The mixture was
transferred to a chilled, 2mm gap electroporation cuvette
(VWR scientiﬁc, Toronto, ON). The bacteria were subjected
to a pulse of 3.5kV, 25μF, at a resistance of 1000Ω [12].
The cuvette was incubated on ice for ten minutes before
the contents were transferred to a separate tube and diluted
with 3ml of Middlebrook 7H9 media (Difco, Detroit, MI)
with 0.5% Tween 80 and OADC supplement (Difco). The
mixture was incubated at 37
◦C for 3h to allow for antibiotic
expression. Cells were harvested by centrifugation at 3000g
for ten minutes and plated on Middlebrook 7H10 agar plates
withOADCand10μg/mlofkanamycin[12].Theplateswere
sealed with paraﬁlm and incubated at 37
◦C for 21–28 days to
allow colonies to grow.
3. Results
Figures 1 and 2 show the number of BCG- and β-gal-
speciﬁcIFNγ-andIL-4-producingcellsinthespleensofmice
nine weeks after immunization with diﬀerent doses of rBCG
(either rBCGβgal or rBCGHgag). Immunization with both
low and high doses of rBCGβgal induced not only BCG-
speciﬁc but also β-gal-speciﬁc cytokine-producing cells,
indicating that the β-gal is expressed in vivo at a level
suﬃcient to induce an immune response. The immune
response to diﬀerent doses of rBCG given by i.v. (Figure 1)
and i.d. (Figure 2) immunization is qualitatively diﬀerent.
Regardless of the route, high doses of rBCGβgal induce a
mixed IFNγ and IL-4 response while lower doses induce
a predominantly IFNγ response to both BCG and the
expressed β-gal antigen. Although the numbers of β-gal-
speciﬁc spot forming cells are low in rBCGβgal immunized
mice, they represent a signiﬁcant portion of the response
to the rBCGβgal, particularly in mice immunized by the
i.d. route. Mice immunized with BCG transformed with a
control vector BCGHgag, not expressing β-gal (Figure 1(d)),4 Journal of Biomedicine and Biotechnology
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Figure 2: Immune response of four individual mice per group after i.d. immunization with diﬀerent doses of recombinant BCGβgal. Mice
were immunized as indicated under each graph, with an unimmunized control shown. After 9 weeks, the mice were killed and the number
of β-gal- and BCG-speciﬁc IFNγ- and IL-4-producing cells in their spleens was determined by ELISPOT assay. Open bars—IFNγ response
to BCG; Black bars—IFNγ response to β-gal; Dark gray bars—IL-4 response to BCG; Light gray bars—IL-4 response to β-gal. All values
were corrected for background by subtracting the number of spots observed in wells without antigen. Results are representative of two
independent experiments.
show no response to β-gal while cells from unimmunized
control mice (shown in Figure 2(d)) do not respond to
either the BCG-lysate antigen or to the β-gal antigen.
Only mice immunized with the high doses of rBCGβgal
had signiﬁcant antibody titers to β-gal (data not shown),
indicating that the antibody response is indeed attributable
to immunization with rBCGβgal, and that only higher
doses induce antibody production. Similarly, high doses of
rBCG were required for induction of BCG-speciﬁc antibody
production, demonstrating that the humoral response to β-
gal follows that induced for the BCG.
We wished to determine if low-dose immunization with
rBCGβgal could establish immune deviation such that the
IFNγ-dominant response initially induced by the low-dose
vaccinationwouldbemaintaineduponsubsequentchallenge
with a dose of rBCGβgal that induces a mixed IFNγ/IL-4
responseinna¨ ıvemice.Miceimmunizedwithdiﬀerentdoses
of rBCG by the i.d. route were challenged four months later
with a high dose of rBCGβgal, also given intradermally. The
immune response was assayed at 16 weeks postchallenge.
Mice that were immunized with low doses by the i.d. route
(Figure 3) maintained a dominant IFNγ response to BCG
antigen and to β-gal after the challenge, which was distinct
from the mixed IFNγ/IL-4 response of control mice that
received only the challenge dose, demonstrating immune
deviation toward a cell-mediated response. The ratio of
IFNγ- to IL-4-producing cells (means within each group)
are depicted in Figure 4. Even after challenge with the high
dose of rBCGβgal, the mice that were immunized previously
with a low dose of rBCG have a tenfold higher IFNγ
response compared to control mice or those mice given
only the high challenge dose. These results demonstrate
that, once established, the dominant IFNγ response induced
by low-dose vaccination is not easily deviated to an IL-
4 response upon challenge. The anti-β-gal serum antibody
titers from the mice of Figure 3 are shown in Figure 5.
Note the prominence of IgG2a antibody in the serum of
mice immunized with a low dose of rBCG before challenge,
compared to the control mice given only the high dose. This
is consistent with the prominence of IFNγ-producing cells in
mice pretreated with low doses of rBCG, as class switching to
IgG2a is associated with IFNγ production in mice [3].Journal of Biomedicine and Biotechnology 5
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Figure 3: Immune response of individual mice vaccinated with diﬀerent doses of rBCGβgal after subsequent i.d. challenge with a high dose
of rBCGβgal. Each group of mice was initially given an i.d. vaccination dose of rBCGβgal as indicated below each graph with a control group
receiving challenge dose only shown. After 4 months, the mice were challenged with approximately 2 × 107 rBCGβgal cfu given i.d. After an
additional 16 weeks, the mice were killed and the number of β-gal- and BCG-speciﬁc IFNγ- and IL-4-producing cells in their spleens was
determined by ELISPOT assay. Open bars—IFNγ response to BCG; Black bars—IFNγ response to β-gal; Dark gray bars—IL-4 response to
BCG; Light gray—IL-4 response to β-gal. All values were corrected for background by subtracting the number of spots observed in wells
without antigen. Results are representative of two independent experiments.
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Figure 4: Ratio of IFNγ to IL-4 spots in the mice depicted in
Figure 3. Ratios were calculated as the mean number of antigen-
speciﬁc IFNγ spots/the mean number of IL-4 spots within each
group of mice. Open circles and ﬁlled circles represent BCG- and
βgal-speciﬁc IFNγ:IL-4 ratios, respectively.
We compared the immune response to β-gal in mice
immunized with rBCGβgal and in mice immunized with
puriﬁed β-gal using other methods that might be acceptable
for immunization of humans. Figure 6 shows the immune
response in mice immunized with puriﬁed β-gal given in
alum as an adjuvant. In both cases, immunization was by
the i.p. route. Soluble β-gal did not induce a signiﬁcant
immune response in any of the mice immunized with
this preparation (data not shown). β-gal in alum, however,
induced predominantly IL-4-producing cells in mice, at
even the low dose used. This is not unexpected as alum
is particularly eﬀective at inducing Th2 responses [13].
However, these results exemplify potential problems in
achieving a desirable Th1 response in humans with current
vaccination procedures.
4. Discussion
Previous studies have shown that the Th1/Th2 phenotype of
the immune response to BCG, generated in very young and6 Journal of Biomedicine and Biotechnology
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Figure 5: Serum antibody responses of mice to β-gal after immunization with diﬀerent doses of rBCG by the i.d. route, and subsequent
challenge with a high dose of rBCG by the same route. Mice were immunized initially with doses indicated below each graph with age-
matched control mice receiving only challenge dose shown. After 16 weeks, all groups were challenged with 2 × 107 rBCG given i.d. Serum
was collected at the time the mice were killed, 16 weeks after the challenge. Open bars show IgG1 titers while black bars depict IgG2a titers.
in adult mice, depends upon the dose of BCG administered,
as assessed following infection by several diﬀerent routes
[10]. Infection with relatively low numbers of BCG generates
a predominant Th1 response and with higher numbers a
mixed Th1/Th2 response. Here we show that the Th1/Th2
phenotypes of the immune responses to BCG and to β-gal
similarly depend upon the number of rBCG employed for
infection and that the Th1/Th2 phenotypes of the responses
to BCG and to β-gal appear to be coherent. Our studies
show that rBCG can be used to preferentially generate a Th1
response to the encoded antigen by infecting with relatively
low doses of rBCG. We now consider the potential use of this
strategy in vaccination against HIV-1 and inﬂuenza viruses.
In looking at current views, it appears that there are
two main, contradictory, positions as to how eﬀective
vaccination against HIV-1 might be achieved. Most suggest
the combination of cell-mediated immunity, in the form
of CTL and neutralizing antibody, will provide optimal
protection. Thus, vaccination should ensure such a response
is mounted upon natural exposure to the virus. It is well
known that neutralizing antibody can be generated, but
that HIV-1 has a means of generating viral variants very
quickly. As such, neutralizing antibody generated against the
original variant encountered will be eﬀective against this
particular variant, but usually is ineﬀective against newly
arising variants that become dominant through the course
of the infection.
The contrasting view we favor is that vaccination, in
order to be eﬀective, must guarantee a predominant Th1
response, associated with potent CTL generation, upon
HIV-1 infection. We think three lines of reasoning support
this view. Firstly, there are highly exposed and infected
individuals who produce predominant and stable Th1, CTL
responses, but who are symptom-free. A prime illustration
o fs u c hag r o u pi sac o h o r to ff e m a l es e xw o r k e r si nN a i r o b i ,
whose immune state has been extensively characterized [14,
15]. What is additionally remarkable about this group of
individuals is that they do not seroconvert and remain
healthy over many years despite numerous exposures to
major viral variants or clades of HIV-1 due to the nature
of their work. Secondly, all individuals infected with HIV-
1 are healthy during the period when their immune systemJournal of Biomedicine and Biotechnology 7
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Figure 6: Number of IFNγ- and IL-4-producing cells in mice
immunized i.p. with soluble β-gal (A) and β-gal adsorbed to alum
as an adjuvant (B). Soluble β-gal was administered twice ﬁve
days apart, while β-gal/alum was administered only once. Dose
of β-gal administered in each experiment is indicated (10μgo r
100μg). Mice were killed 11 days after the initial injection, and
antigen-speciﬁc cytokine-producing spleen cells were enumerated
by ELISPOT assay. Open bars represent IFNγ spots and black bars
represent IL-4 spots. Results are representative of three separate
experiments.
mounts a predominant Th1, CTL response, before they
seroconvert and enter the progressive stages of disease
[16]. Both observations strongly support the idea that a
predominant Th1, CTL response can contain HIV-1. Why
then not aim for having the best of both worlds, both
CTL and neutralizing antibody, as most suggest? It is an
assumption, and one that we feel is highly questionable,
that this is possible. Distinct CD4+ T cell subsets tend to
inhibiteachothers’generationandofteneachothers’eﬀector
activities [1]. It may not be possible to have the best of both
worlds, involving a mixed Th1/Th2 response, with optimal
production of CTL immunity and neutralizing antibody.
We think it best to conclude, in accordance with natural
situations in which the virus is contained, and infected
individuals remain symptom-free, that a predominant Th1,
CTL response is optimally protective. We employ this
proposition as a starting point for considering how eﬀective
vaccination might be achieved.
In the case of inﬂuenza virus, that causes an acute
infection, it seems antibody can be highly protective.
Antibody is usually not produced in suﬃcient amounts
upon infection of na¨ ıve individuals to prevent pathological
symptoms, which is why immunization against the virus
causing the current epidemic is eﬀective in preventing
illness. Individuals who have been infected during the last
epidemic, but not immunized against the virus causing the
current epidemic, are highly primed to produce antibody.
The antibody produced is highly eﬀective in neutralizing
the inﬂuenza strain causing the previous epidemic, but not
the virus causing the current epidemic. This makes eminent
sensefromanepidemiologicalpointofview.Itisjustbecause
the current inﬂuenza strain can stimulate the production
of this antibody, ineﬀective in its own neutralization, that
the virus can multiply unimpeded in the individual, primed
by a previous infection, with the consequential spread of
the virus through the population. An appreciation of these
facts underlies the formulation of current policy. The aim
is to achieve immunization against the strain causing the
current epidemic as soon as it has been identiﬁed. This
policy is sound, but its realization is extremely expensive
and poses considerable logistical problems, clearly illustrated
throughout the most recent inﬂuenza H1N1 pandemic.
The CTL response against inﬂuenza involves, in large
measure, a response against peptides derived from viral
proteins that do not vary greatly between strains, such as
peptides derived from the nuclear protein, NP [17]. The
possibility might therefore be considered that vaccination
resulting in a sustained and eﬀective CTL response upon
infection by diverse variants might be eﬀective against all
variants. An intriguing report supports this possibility. DNA
immunization of mice against NP results in a predominant
Th1, CTL response on challenge with diﬀerent viral variants
and resistance [18]. Thus generating stable Th1 imprints
against inﬂuenza might result in protection against diverse
viral variants.
The observations reported here and our considerations
on how vaccines against diverse clades of HIV-1 and strains
of inﬂuenza might be achieved by causing Th1 imprints
lead us to suggest that attempts at realizing a low-dose
rBCG vaccination strategy is worthy of further exploration.
We showed in this paper that infection with low numbers
of rBCG generated not only predominant Th1 responses
but also Th1 imprints as assessed by the predominant Th1
responses observed upon a subsequent challenge with a high
number of rBCG that generate mixed Th1/Th2 responses
in na¨ ıve animals. We consider the next important step in
assessing the plausibility of this strategy will be to examine
whether rBCG can provide protection against a pathogenic
infection.Therearemousemodelsofinﬂuenzainfection.We
hope to examine, employing established systems, whether
infection of mice with low numbers of rBCG vectors,
encoding conserved proteins of inﬂuenza virus, can generate
Th1 imprints, as assessed by infection with a normally8 Journal of Biomedicine and Biotechnology
pathogenic challenge of inﬂuenza virus, and whether such
imprints provide protection against diverse viral variants.
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